3 Million+ Unique Research Compounds, Real-time Pricing & Availability
Sign in to enjoy up to 20% OFF or Sign Up
  • Product Search
     
[email protected]
  • Product Search
     
Chemistry
Bioactive Molecules
Screening Libraries
Natural Products
Material Science
ADCs
PEG
Antibodies
Consumables
+1 800-931-7508 [email protected]
Sign in to enjoy up to 20% OFF

[CAS NO. 23541-50-6]  Daunorubicinhydrochloride

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [23541-50-6]

Store
Catalog
HY-13062
Brand
MCE
CAS
23541-50-6

DESCRIPTION [23541-50-6]

Overview

MDLMFCD04974507
Molecular Weight563.98
Molecular FormulaC27H30ClNO10
SMILESO=C(C(C(OC)=CC=C1)=C1C2=O)C3=C2C(O)=C(C[C@@](O)(C(C)=O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O.[H]Cl

For research use only. We do not sell to patients.

19 Publications Citing Use of MCE


Summary

Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis . Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis . Daunorubicin hydrochloride is also an anthracycline antibiotic . Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor [1] [2] [4] [5] .


IC50 & Target

Topoisomerase II

Daunorubicins/Doxorubicins


In Vitro

Daunorubicin hydrochloride (0-256 μg/mL, 30 min) inhibits DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells [2] .
Daunorubicin hydrochloride (7 nM-1.9 μM, 72 h) shows chemosensitivity in Molt-4 cells and L3.6 cells [3] [4] .
Daunorubicin hydrochloride (0.4 μM, 48 h) induces apoptotic and necrosis in L3.6 cells [4] .
Daunorubicin hydrochloride (0.4 μM, 120 min) induces ROS generation in L3.6 cells [4] .
Daunorubicin hydrochloride (2 μM, 24 h) induces autophagy in K562 cells (myeloid cell line) [6] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay [3] [4]

Cell Line: Molt-4 cells (a human T-lymphoblastic leukemia cell line), L3.6 cells (metastatic human pancreatic cell line)
Concentration: 7 nM-1.9 μM
Incubation Time: 72 h
Result: Inhibited cell viability with IC 50 values of 40 nM (Molt-4) and 400 nM (L3.6).

Apoptosis Analysis [4]

Cell Line: L3.6 cells
Concentration: 0.4 μM
Incubation Time: 72 h
Result: Induced necrosis without apoptosis at 24 h, induced both an apoptotic and extensive necrotic response at 48 h.

Western Blot Analysis [6] :

Cell Line: K562 cells
Concentration: 2 μM
Incubation Time: 24 h
Result: Enabled the switch of LC3-I into LC3-II, accompanied with a significant increased expression level of LC3.

In Vivo

Daunorubicin hydrochloride (intravenous injection, 3 mg/kg, three times at 48 h intervals.) produces cardiotoxicity and nephrotoxicity in rats [5] .
Daunorubicin hydrochloride (intraperitoneal injection, 10 mg/kg) induces sister chromatid exchanges in mice [7] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats [5]
Dosage: 3 mg/kg
Administration: Intravenous injection, three times at 48 h intervals.
Result: Caused a significant increase in MDA (malondialdehyde) level in renal tissue, accompanied by a significant reduction in total GPx activity.
Increased urinary protein excretion, serum creatinine, and BUN level.

Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT02894645 National University Hospital, Singapore
Acute Lymphoblastic Leukemia (ALL)
October 2008 Phase 4
NCT00764907 University Hospital, Motol|National Cancer Institute (NCI)
Leukemia
November 2002 Phase 3
NCT03709758 Dana-Farber Cancer Institute|AbbVie|Genentech, Inc.
Acute Myeloid Leukemia
October 17, 2018 Phase 1

Appearance

Solid


Source

Streptomyces coeruleorubidus


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)


Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 88.66 mM ; Need ultrasonic)

H 2 O : ≥ 34 mg/mL ( 60.29 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.7731 mL 8.8656 mL 17.7311 mL
5 mM 0.3546 mL 1.7731 mL 3.5462 mL
10 mM 0.1773 mL 0.8866 mL 1.7731 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: PBS

    Solubility: 33.33 mg/mL (59.10 mM); Clear solution; Need ultrasonic

  • 2.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.08 mg/mL (3.69 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (3.69 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride (1:1), (8S,10S)-
Daunomycin, hydrochloride
5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8S-cis)-
5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8S,10S)-
Daunorubicin hydrochloride
Daunomycin chlorohydrate
Daunoblastin
Ondena
Cerubidine
Rubidomycin hydrochloride
NDC 0082-4155
RP 13057 hydrochloride

Information
Shipping
Privacy notice
Terms of Service
About us
Contact us
FAQs
Customer service
Search
Custom Synthesis
My account
My account
Orders
Addresses
Shopping cart
Suppliers
Supplier Sign In
Become a Supplier
Pay
Follow us
Powered by Arctom Copyright © 2026 Arctom. All rights reserved.